Form 4: AtriCure Director Sells Shares Under 10b5-1 Plan

AtriCure Director Maggie Yuen reported the sale of 3,000 shares of common stock at a weighted average price of $35.72 per share on November 21, 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Maggie Yuen, a Director of AtriCure, Inc. (ATRC), reported the sale of 3,000 shares of common stock.
• The transaction occurred on November 21, 2025.
• The shares were sold at a weighted average price of $35.72 per share, with trades ranging from $35.71 to $35.76.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-scheduled.
• Following the transaction, Maggie Yuen beneficially owns 11,371 shares of AtriCure common stock directly.

Sentiment

Score: 5

Explanation: A director's sale of shares, while a reduction in insider holdings, was executed under a pre-arranged 10b5-1 plan, which typically suggests the transaction is for personal financial planning rather than a reaction to new company-specific information. This makes the sentiment neutral.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new, non-public information, which mitigates potential negative interpretations of insider selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a reduction in insider confidence or a signal of limited upside potential, though this is largely mitigated by the pre-planned nature.

Future Outlook

NA

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis for AtriCure, Inc.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor signal regarding insider sentiment, though the execution under a 10b5-1 plan suggests it is not based on new, material non-public information.

Key Dates

Recommendation

This Form 4 reports a routine insider sale by a director under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial management and do not necessarily reflect a change in the director's outlook on the company's future performance. Without additional information or context, this filing alone does not warrant a change in investment recommendation.

Keywords

AtriCure, ATRC, insider trading, Form 4, stock sale, director, 10b5-1 plan, beneficial ownership